Bionano Genomics (BNGO) Liabilities and Shareholders Equity (2017 - 2026)

Bionano Genomics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $64.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 17.36% year-over-year to $64.8 million; the TTM figure through Mar 2026 stood at $293.5 million (down 21.07% YoY), while the FY2025 annual figure was $73.6 million, down 4.03% from the prior year.
• Liabilities and Shareholders Equity came in at $64.8 million for Q1 2026 at Bionano Genomics, down from $73.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $348.2 million in Q1 2022 to a low of $64.8 million in Q1 2026.
• A 5-year average of $181.4 million and a median of $158.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 64.24% in 2024 and slipped 4.03% in 2025, its largest moves.
• Bionano Genomics' Liabilities and Shareholders Equity stood at $307.5 million in 2022, then sank by 30.28% to $214.4 million in 2023, then sank by 64.24% to $76.7 million in 2024, then decreased by 4.03% to $73.6 million in 2025, then retreated by 11.93% to $64.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $64.8 million, $73.6 million, and $79.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison